New drug combo aims to outsmart aggressive colon cancer
NCT ID NCT07412613
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 3 trial is testing whether adding the immunotherapy drug AK104 (cadonilimab) before and after surgery can improve outcomes for people with a specific type of colon cancer (MSI-H/dMMR). About 386 participants will be randomly assigned to receive either AK104 plus standard chemotherapy or chemotherapy alone. The main goals are to see if the cancer disappears completely after treatment and if it delays the cancer from coming back.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Cadonilimab (AK104), a drug that helps the immune system fight cancer, plus standard chemotherapy drugs (oxaliplatin, capecitabine, 5-fluorouracil, calcium folinate)
- What this could lead to
- If this works, it could offer a more effective treatment option for people with a specific type of colon cancer, potentially reducing the chance of cancer coming back after surgery.
- What could go wrong
- This is an early-phase 3 trial, so results are not yet known. The new drug may not work better than standard chemo, and it could cause side effects like immune-related inflammation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MSI-H/DMMR COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.